Skip to main
MGX
MGX logo

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc. is advancing its gene editing technologies, demonstrating significant durability with FVIII levels sustained at 80% over a 19-month period in its non-human primate model, indicating strong therapeutic potential for Hemophilia A treatment. The company's comprehensive suite of proprietary genome editing tools positions it uniquely in the genetic medicines sector, facilitating both in vivo gene editing for its pipeline and pursuit of technology out-licensing for ex vivo applications. With a robust pipeline targeting serious health conditions such as Refractory Hypertension and Wilson's disease, Metagenomi is well-positioned for future growth driven by its innovative therapeutics.

Bears say

Metagenomi Inc. reported a significant net loss of $19.9 million for the second quarter of 2025, equating to a loss of $0.54 per share, which raises concerns about the company's financial stability. Despite trading below its cash value, indicating potential upside, the company faces substantial risks including delays in clinical advancement and the possibility of unfavorable clinical data, particularly for key pipeline candidates like MGX-001 targeting Hemophilia A. Additionally, the potential for long-term dilution poses further challenges to shareholder value and may hinder investor confidence in the company’s future performance.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.